🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Thank you for your help with this important WebMD story Mike Foote and for the crucial lifesaving research you and your team are doing Memorial Sloan Kettering Cancer Center!

Top 100 Xfluencers in Colorectal Cancer: Key Opinion Leaders to follow on X (Twitter) in 2024 #Cancer #ColorectalCancer #OncoDaily #Oncology #Xfluencers #CancerCare oncodaily.com/41402.html

Very excited to be part of this event!

The registrational enabling Spearhead-1 study shows that afami-cel, an engineered T cell targeting MAGEA4, has promising efficacy in synovial sarcoma and MRCLS paving the way for T cell therapy in solid tumors. Memorial Sloan Kettering Cancer Center MSK Department of Medicine Sarcoma Service at Memorial Sloan Kettering sciencedirect.com/science/articl…

Hope to see many of our Lynch syndrome community on 4/9!

Congratulations to Dr. Andrea Cercek, a gastrointestinal oncologist at MSK, who was named to the inaugural 2024 TIME 100 Health, a new annual list of 100 individuals who most influenced global health this year. #TIME100Health

🆕 🗞️ Annals of Oncology The largest series to date on POL-E or POLD1 (proofreading-deficient) metastatic #ColorectalCancer and the use of #immunotherapy. Tumors➡️MSS but have a very high TMB (ultra-hyper-mutated - TMB > 100 Mut/Mb). ESMO - Eur. Oncology OncoAlert sciencedirect.com/science/articl…

Fantastic presentation by Neil Segal from MSK Department of Medicine of a novel EGFR-CD28 bispecific antibody with cemiplimab in MSS CRC with activity, particularly in patients without liver metastases (20%!). Exciting and promising new modality for our patients #ASCO24

Rona Yaeger Congratulations 🎉🎈🎊 Amazing 🤩 work !!! So proud of you Rona and appreciate our collaboration in #KRAS

Molecular and Clinicopathologic Impact of GNAS Variants Across Solid Tumors: brnw.ch/21wLYNy Mike Foote #gicsm

Fascinating study by Benoit Rousseau and Luis Diaz examining the duration of immune checkpoint blockade in MMRD early stage tumors. Six months seems to be the magic number for complete response rate!

New research by John Paul Shen & Mike Foote reveals that #appendixcancer is distinct from colorectal cancer, requiring different treatment approaches. Promising trials explore targeted therapies for better outcomes. Learn more: dailynews.ascopubs.org/do/appendix-ca…

ICYMI: John Paul Shen of MD Anderson Cancer Center and Mike Foote of Memorial Sloan Kettering Cancer Center discuss how appendix cancer differs from CRC and examine new potential targeted treatments: brnw.ch/21wS5hM #ASCODailyNews

Presented at #AACR25: Neoadjuvant PD-1 blockade with dostarlimab led to organ preservation in a high proportion of patients with early-stage mismatch repair–deficient tumors, with no compromise of surgical options. Full study results: nej.md/3EsWcoi  AACR

New research presented by MSK gastrointestinal medical oncologist Yelena Y. Janjigian MD at #AACR25 shows that a simple blood test can help doctors identify which patients are most likely to benefit from #immunotherapy after cancer surgery to remove tumors — potentially preventing the

An approach pioneered at MSK that caused #rectalcancer tumors with a specific genetic mutation to disappear in 100% of clinical trial participants has been expanded to treat other types of cancer, including stomach (gastric), colon, esophageal, urothelial, and others.

New paper from our team at Memorial Sloan Kettering Cancer Center. Nonoperative Management of Mismatch Repair–Deficient Tumors | New England Journal of Medicine nejm.org/doi/10.1056/NE…

Congratulations to our team. Next chapter in Nonoperative Management of Mismatch Repair–Deficient Tumors | New England Journal of Medicine nejm.org/doi/10.1056/NE…

🚨 New research from ASCO: A clinical trial led by Yelena Y. Janjigian MD, Chief of Gastrointestinal Medical Oncology at MSK, has demonstrated a powerful new approach to help prevent cancer from coming back after treatment for #stomachcancer and #cancer of the lower portion of the